Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TG Therapeutics Inc (TGTX) vs Zscaler Inc (ZS) Price & Performance

TG Therapeutics IncTrade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

TG Therapeutics Inc vs Zscaler Inc — how do they compare? TG Therapeutics Inc trades at $50 (market cap $7.58B), while Zscaler Inc trades at $178.13 (market cap $28.67B). The key difference: Zscaler Inc is far larger — about 3.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.

TGTXZS
Market Cap
$7.58B$28.67B
Sector
HealthTechnology
52-Week High
$59.06$336.27
52-Week Low
$26.94$118.05
Enterprise Value
$7.78B$27.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Zscaler Inc

Zscaler (ZS) trades at $176.94, up 0.15% with strong bullish technical signals and positive analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though it remains unprofitable with a -2.44% net margin. Recent earnings beats and leadership in Gartner Magic Quadrant for SASE platforms highlight operational strength. Current price sits near resistance at $177 with RSI indicating overbought conditions.

Outlook remains positive with 79% analyst buy ratings and $191.81 consensus target, but risks include negative profitability, high valuation multiples (P/S 8.94), and projected negative cash flow in 2026. The cybersecurity leader benefits from AI-driven security demand but faces execution risks amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS